vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $257.2M, roughly 1.1× WESBANCO INC). WESBANCO INC runs the higher net margin — 34.5% vs -45.7%, a 80.1% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 29.2%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
GH vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $257.2M |
| Net Profit | $-128.5M | $88.6M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 34.5% |
| Revenue YoY | 39.4% | — |
| Net Profit YoY | -15.8% | 54.4% |
| EPS (diluted) | $-1.01 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $281.3M | $265.6M | ||
| Q3 25 | $265.2M | $261.6M | ||
| Q2 25 | $232.1M | $260.7M | ||
| Q1 25 | $203.5M | $193.2M | ||
| Q4 24 | $201.8M | $162.9M | ||
| Q3 24 | $191.5M | $150.8M | ||
| Q2 24 | $177.2M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-128.5M | $91.1M | ||
| Q3 25 | $-92.7M | $83.6M | ||
| Q2 25 | $-99.9M | $57.4M | ||
| Q1 25 | $-95.2M | $-9.0M | ||
| Q4 24 | $-111.0M | $49.6M | ||
| Q3 24 | $-107.8M | $37.3M | ||
| Q2 24 | $-102.6M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 43.2% | ||
| Q3 25 | -37.3% | 39.5% | ||
| Q2 25 | -45.9% | 27.2% | ||
| Q1 25 | -54.6% | -5.0% | ||
| Q4 24 | -62.4% | 38.0% | ||
| Q3 24 | -61.3% | 29.7% | ||
| Q2 24 | -56.8% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -45.7% | 34.3% | ||
| Q3 25 | -35.0% | 31.9% | ||
| Q2 25 | -43.0% | 22.0% | ||
| Q1 25 | -46.8% | -4.7% | ||
| Q4 24 | -55.0% | 30.5% | ||
| Q3 24 | -56.3% | 24.7% | ||
| Q2 24 | -57.9% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-1.01 | $0.97 | ||
| Q3 25 | $-0.74 | $0.84 | ||
| Q2 25 | $-0.80 | $0.57 | ||
| Q1 25 | $-0.77 | $-0.15 | ||
| Q4 24 | $-0.90 | $0.72 | ||
| Q3 24 | $-0.88 | $0.54 | ||
| Q2 24 | $-0.84 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $4.1B |
| Total Assets | $2.0B | $27.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | $956.1M | ||
| Q3 25 | $580.0M | $1.0B | ||
| Q2 25 | $629.1M | $1.2B | ||
| Q1 25 | $698.6M | $1.1B | ||
| Q4 24 | $525.5M | $568.1M | ||
| Q3 24 | $585.0M | $620.9M | ||
| Q2 24 | $933.7M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $-99.3M | $4.0B | ||
| Q3 25 | $-354.5M | $4.1B | ||
| Q2 25 | $-305.5M | $3.8B | ||
| Q1 25 | $-250.8M | $3.8B | ||
| Q4 24 | $-139.6M | $2.8B | ||
| Q3 24 | $-60.1M | $2.8B | ||
| Q2 24 | $-1.6M | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $2.0B | $27.7B | ||
| Q3 25 | $1.3B | $27.5B | ||
| Q2 25 | $1.3B | $27.6B | ||
| Q1 25 | $1.3B | $27.4B | ||
| Q4 24 | $1.5B | $18.7B | ||
| Q3 24 | $1.5B | $18.5B | ||
| Q2 24 | $1.6B | $18.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $290.4M | ||
| Q3 25 | $-35.4M | $116.9M | ||
| Q2 25 | $-60.3M | $105.0M | ||
| Q1 25 | $-62.7M | $-26.4M | ||
| Q4 24 | $-64.5M | $211.0M | ||
| Q3 24 | $-51.1M | $60.7M | ||
| Q2 24 | $-94.0M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $280.0M | ||
| Q3 25 | $-45.8M | $114.9M | ||
| Q2 25 | $-65.9M | $98.3M | ||
| Q1 25 | $-67.1M | $-30.7M | ||
| Q4 24 | $-83.4M | $200.7M | ||
| Q3 24 | $-55.3M | $56.9M | ||
| Q2 24 | $-99.1M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 105.4% | ||
| Q3 25 | -17.3% | 43.9% | ||
| Q2 25 | -28.4% | 37.7% | ||
| Q1 25 | -33.0% | -15.9% | ||
| Q4 24 | -41.3% | 123.2% | ||
| Q3 24 | -28.9% | 37.7% | ||
| Q2 24 | -55.9% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 3.9% | ||
| Q3 25 | 3.9% | 0.8% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 2.2% | 2.2% | ||
| Q4 24 | 9.4% | 6.3% | ||
| Q3 24 | 2.2% | 2.5% | ||
| Q2 24 | 2.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | — | 1.63× | ||
| Q2 24 | — | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
